Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
Moffitt Cancer Center
•
HR+
•
NCI-CCC Breast Tumor Board Question
•
Breast Cancer, Non-metastatic
•
Primary Care
How do you council patients diagnosed with hormone receptor-positive breast cancer currently or interested in taking exogenous hormones (e.g. testosterone) for gender-affirming treatment?
Related Questions
Would you offer adjuvant ribociclib to a postmenopausal female with ER+ luminal A, node+ breast cancer pT1cN1a grade 2 that didn't require chemotherapy per OncoType, but met NATALEE inclusion criteria?
How do you assess and counsel women with chronic post-lumpectomy or mastectomy pain?
What approach is suggested for extended adjuvant endocrine therapy in a hormone receptor-positive breast cancer?
What are your top takeaways in Medical Oncology from SABCS 2025?
What is your approach to adjuvant chemotherapy for a postmenopausal woman with pT1cN0 grade 2 ER+ breast cancer (IDC) and OncoType RS of 25?
Would you consider adding adjuvant ribociclib for a patient who has already received 2 years of endocrine therapy and is eligible for ribociclib according to the NATALEE trial?
In the current era of adjuvant CDK4/6 inhibitor use for high-risk HR+/HER2-negative breast cancer, what is the preferred adjuvant chemotherapy regimen for premenopausal women — AC-T or TC?
What adjuvant therapy would you recommend for a woman in her 90s with ER-positive, HER2-positive breast cancer who received neoadjuvant trastuzumab, pertuzumab, and anastrozole, but did not achieve a pathologic complete response?
What additional risk features, if any, would sway you to offer chemotherapy in premenopausal women with ER+ HER2- node positive patients whose Oncotype is < 11?
What treatment would you recommend for a patient with early-stage TNBC treated per KEYNOTE-522, PD-L1 CPS >10, with metastatic recurrence within 12 months of treatment completion?
